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Abstract: Wnt signaling plays a major role in bone metabolism. Advances in our understanding of
secreted regulators of Wnt have yielded several therapeutic targets to stimulate osteoanabolism—the
most promising of which is the Wnt inhibitor sclerostin. Sclerostin antibody recently gained approval
for clinical use to treat osteoporosis, but the biology surrounding sclerostin antagonism is still
incompletely understood. Numerous factors regulate the efficacy of sclerostin inhibition on bone
formation, a process known as self-regulation. In previous communications we reported that the basic
helix-loop-helix transcription factor Twist1—a gene know to regulate skeletal development—is highly
upregulated among the osteocyte cell population in mice treated with sclerostin antibody. In this
communication, we tested the hypothesis that preventing Twist1 upregulation by deletion of Twist1
from late-stage osteoblasts and osteocytes would increase the efficacy of sclerostin antibody treatment,
since Twist1 is known to restrain osteoblast activity in many models. Twist1-floxed loss-of-function
mice were crossed to the Dmp1-Cre driver to delete Twist1 in Dmp1-expressing cells. Conditional
Twist1 deletion was associated with a mild but significant increase in bone mass, as assessed by
dual energy x-ray absorptiometry (DXA) and microCT (µCT) for many endpoints in both male and
female mice. Biomechanical properties of the femur were not affected by conditional mutation of
Twist1. Sclerostin antibody improved all bone properties significantly, regardless of Twist1 status, sex,
or endpoint examined. No interactions were detected when Twist1 status and antibody treatment
were examined together, suggesting that Twist1 upregulation in the osteocyte population is not
an endogenous mechanism that restrains the osteoanabolic effect of sclerostin antibody treatment.
In summary, Twist1 inhibition in the late-stage osteoblast/osteocyte increases bone mass but does not
affect the anabolic response to sclerostin neutralization.
Keywords: Twist1; sclerostin; Wnt; osteoporosis; osteocytes; mechanotransduction
1. Introduction
The search for osteoanabolic targets in bone tissue has produced few clinically viable candidates
despite the paucity of, and need for, anabolic therapies to treat a variety of bone diseases [1]. Until
very recently, only two anabolic agents were approved for clinical use (teriparatide and abaloparatide),
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both of which use a common mechanism to achieve increased bone formation—stimulation of the
parathyroid hormone/parathyroid hormone-related receptor PTH1R [2]. These therapies require daily
injections and are efficacious only for around 18 months of treatment. Other options for stimulating
new bone formation are needed.
A greater understanding of the Wnt signaling pathway in the context of bone tissue has revealed
new opportunities for building bone in the skeleton. The rationale for targeting Wnt components to
improve bone properties comes from several human mutations that result in increased bone mass,
including loss-of-function mutations in the SOST gene (e.g., sclerosteosis) [3], loss-of-function mutations
in the LRP4 gene (e.g., sclerosteosis type 2) [4], and gain-of-function mutations in the LRP5 gene
(e.g., endosteal hyperostosis, or high bone mass (HBM) disease) [5]. Sclerostin, the secreted inhibitor of
Wnt–Lrp5/6 signaling (encoded by the SOST gene), has gained the most traction as a target to increase
bone mass for reasons that include high bone specificity of the protein, very high potency (as revealed
by the severe osteosclerotic phenotype among patients that fail to synthesize sclerostin), and the fact
that sclerostin is a secreted protein that interacts extracellularly, which renders it amenable to targeting
with biologics [6]. Neutralizing antibodies to sclerostin have had great success in phase III trials
for postmenopausal osteoporosis [7], and a sclerostin neutralizing antibody—Romosozumab—was
recently approved for clinical use in Japan, the US, South Korea, Canada, and Australia [8].
While sclerostin neutralization is unequivocally efficacious in stimulating new bone formation,
the mechanisms of action and associated biology are less clear. We and others have reported that
sclerostin inhibition triggers the expression of other Wnt inhibitors (e.g., Dkk1) that ultimately limit the
potency of sclerostin neutralization [9,10]. Disabling some of the accessory Wnt inhibitory mechanisms
can produce a synergistic effect on bone formation that is well beyond the individual or even additive
effects of Wnt inhibitors. We and others have also reported that many genes exhibit changes in
expression level in response to sclerostin neutralization [11–13]. One of the most consistent and most
highly upregulated transcripts in osteocytes among mice exposed to sclerostin antibody is the basic
helix-loop-helix (bHLH) transcription factor Twist1 [11,13]. Twist1 haploinsufficiency in humans
causes Saethre-Chotzen syndrome, characterized by premature fusion of the cranial vault bones and
distal limb skeletal deformities, among other developmental defects [14]. Twist1 overexpression
inhibits osteoblast differentiation in vivo [15] and in vitro [16], whereas Twist1 knockdown increases
osteoblast differentiation and mineralization in vitro [17]. Thus, we surmised that Twist1 upregulation
in sclerostin-deprived osteocytes (e.g., in antibody-treated mice) might be another self-regulation
mechanism that limits the otherwise fuller anabolic potential of sclerostin neutralization. We studied
the skeletal phenotype of mice with conditional deletion of Twist1 in the late-stage osteoblast/osteocyte
population using Dentin Matrix Protein-1 Cre (10kbDmp1-Cre) to recombine homozygous Twist1
loss-of-function alleles (Twist1f/f). Further, we tested the efficacy of sclerostin-neutralizing antibody
in the conditional mice, which were unable to upregulate Twist1 in response to antibody treatment.
We found that although the conditional mutant mice had increased bone mass, sclerostin antibody
treatment resulted in equivalent gains in bone mass regardless of osteocytic Twist1 status. Therefore, it is
unlikely that increased Twist1 expression in the osteocyte limits the efficacy of sclerostin neutralization.
2. Results
2.1. Twist1 Induction in Scl-Ab-Treated Mice
We have previously reported a significant increase in Twist1 expression in sclerostin antibody
(Scl-Ab)-treated mice, based on high-throughput sequencing of the osteocyte transcriptome [11].
To repeat and validate this result in a more quantitative assay, we treated WT mice with a single
injection of Scl-Ab and measured Twist1 expression in the long bone cortices via qPCR 2 days later.
In addition, to address whether Twist1 regulation might be generally Wnt responsive (e.g., also
responsive to suppression of other Wnt inhibitors) in bone, or if its regulation is more selective
compared to other Wnt inhibitors, a Dkk1 antibody (Dkk1-Ab) group was included as a separate
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treatment. Twist1 was significantly upregulated by Scl-Ab but not by Dkk1-Ab, as compared with the
saline injection (Figure 1A).
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Figure 1. (A) Twist1 expression, normalized to the housekeeper Rplp2, was significantly increased in
osteocyte-enriched bone tissue lysates from 10-wk-old female WT C57Bl/6J mice that were injected
with a single dose of 25 mg/kg sclerostin antibody (Scl-Ab), then sacrificed 2 days later. The same
procedure using Dkk1 antibody (25 mg/kg) did not change Twist1 expression; n = 4/group, * p < 0.05.
(B) Representative micrographs of β-galactosidase-reacted femora from Twist1f/f mice that also carried
the Rosa26-LacZ Cre reporter line. Qualitatively, negligible lacZ staining is apparent in the Cre-negative
mice, but the mice positive for 10kbDmp1-Cre exhibit a strong reaction in the bone tissue, indicating
recombination activity of the Cre transgene. (C) Top: schematic showing the floxed Twist1 locus (2
exons) and the location within exon 1 of the forward and reverse primers (arrows) used to probe for the
intact floxed allele in genomic DNA from cortical bone. Bottom: ratio of intact Twist1 sequence (target)
to Apolipoprotein B sequence (control), in Cre-positive and Cre-negative mice; n = 8–9/group, * p < 0.05.
To study Twist1 deficiency in the osteocyte, while avoiding lethality and/or developmental
defects that arise from global mutant alleles (e.g., null [18], hypomorphic [19]) or from conditional
alleles targeted to early stage mesenchymal cells (e.g., Prx1-Cre × Twist1 flox), we crossed the
10kbDmp1-Cre driver onto a Twist1f/f background. Inclusion of the Rosa26-LacZ reporter allele in the
breeding sche e revealed r combinati n in bone, as indicat d by strong β-gal ctosidase staining in
10kbDmp1-Cre-positive (but not negative) femora (Figure 1B). Further, no limb patt rning defects were
f und i the Cre-positive mice (data not shown), which was consistent with Dmp1 expression in the
lat -stage mesenchymal-lineage cell (e.g., late-stage osteoblast and osteocyte). Cortical bone genomic
D A was a sayed for the intact Twist1 allele, which was found in ~60% of the Cre-positive extr cts,
compared to Cre-negative extracts (Figure 1C).
2.2. Mice with Loss-of-Function Twist1 Alleles in Dmp1-Expressing Cells Have a Late-Onset Increase in Bone
Mineral Density, with Similar Response to Sclerostin Neutralization as Control Mice
To determine the skeletal effects of late-stage Twist1 deletion in bone, changes in bone mineral
density (BMD) among mice with 10kbDmp1-Cre-driven inactivation of Twist1 were compared to those
of Cre-negative mice by considering only the vehicle-treated groups. Serial whole-body DEXA scans
were collected from all experimental mice intermittently from 4 to 16 wk of age. Repeated measures
ANOVA using all time points collected indicated that Cre-positive mice had significantly increased
BMD only for the whole-body ROI in males, and the lower-limb ROI in females (Figure 2). However,
when just the later time points (beyond 6 wk of age) were analyzed, significant increases in BMD
were found among the Cre-positive mice for all ROIs examined with the exception of the lower-limb
ROI among males. Body weight was not different among males, but female Cre-positive mice were
significantly heavier than Cre-negative mice (Figure S1).
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Figure 2. Serial in vivo DXA scans of Cre-negative (solid lines) and 10kbDmp1-Cre-positive (broken
lines) Twist1f/f mice, treated twice per week with vehicle control (open circles) or 25 mg/kg sclerostin
antibody (Scl-Ab; filled circles). Scans were collected every 2–4 wk and analyzed for (A,D) whole-body
BMD, (B,E) lumbar spine BMD, and (C,F) BMD of the right hindlimb distal to the acetabulum. Panels
A–C display data from female mice; panels D–F display data from male mice. Antibody/vehicle
treatment began at 10 wk of age, indicated by the vertical arrow. The longitudinal data were tested for
significance of both main effects and an interaction using rmANOVA, reported in the corner of each
panel; n = 8–11/group.
Five weeks of treatment with Scl-Ab significantly increased BMD at all ROIs, in both sexes, in
both Twist1 replete (Cre-negative) and Twist1 compromised (Cre-positive) mice. By the end of the
experiment, BMD was 17–20% greater in the lower limb, 31–38% greater in the spine, and 22–24%
greater for the whole body among Scl-Ab-treated mice compared to the genotype/sex-matched vehicle
controls. Two-way ANOVA failed to identify a significant interaction term for any of the DXA outcome
variables, suggesting that the Twist1 bone deletion did not significantly change the influence of Scl-Ab
on densitometric properties.
2.3. Twist1 Conditional Mutant Mice Have Improved Cortical Bone Properties and Sex-Specific Changes in
Cancellous Bone, but Have Similar Architectural Response to Scl-Ab as Control Mice
To probe compartment-specific effects of both the Twist1 mutation alone and the response to
Scl-Ab in diff rent Twist1 backgrounds, the femur and spine were scan ed via µCT to collect dis al
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femur and L5 cancellous properties and midshaft femur cortical properties. Bone volume fraction
(BV/TV), trabecular thickness and spacing (Tb.Th and Tb.Sp) and bone mineral content (BMC) were
significantly improved by the Twist1 mutation in female but not male mice (Figure 3). No changes in
spine cancellous properties were detected in Twist1 mutants as compared to controls for either sex
(Figure 4). However, cortical bone was improved by Twist1 deletion in both male and female mice,
as indicated by a significant genotype effect for midshaft femur total area (Tt.Ar) and polar moment
(pMOI) (Figure 3). The increase in µCT-derived cortical properties prompted us to test the cortical bone
for biomechanical changes, but no significant genotype-related changes in ultimate force, stiffness, or
energy absorption were found (Figure 5).
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Figure 3. µCT-derived measurement of the distal femur metaphyseal cancellous bone and mid-femur
cortical bone from Cre-negative (white bars) and 10kbDmp1-Cre-positive (grey bars) Twist1f/f mice
at 16 wk of age, treated with or without sclerostin antibody (Scl-Ab) for 6 wk prior to sacrifice.
(A) Representative 3D reconstructions of (top row) the midshaft femur, (middle row) the distal
metaphysis (proximal view), and (bottom row) the caudal half of the distal femur (the ventral half
was digitally removed). Female mice are in the top of the panel, males in the bottom. Quantitative
differences in (B) femur trabecular bone volume fraction (BV/TV), (C) trabecular thickness (Tb.Th),
(D) trabecular bone mineral content (Tb.BMC), and (E) trabecular separation (Tb.Sp) are shown for
female (left side of each panel) and male (right side of each panel) mice. Quantitative differences
in (F) femur cortical bone total area (Tt.Ar), (G) bone area (B.Ar), (H) cortical thickness (Ct.Th), and
(I) polar moment of inertia (pMOI) are shown for female (left side of each panel) and male (right side of
each panel) mice. Data were tested for significance using two-way ANOVA within sex, with Twist1
status and antibody as the main effects (plus interaction), which are reported in the corner or base of
each sex grouping; n = 8–11/group.
Int. J. Mol. Sci. 2019, 20, 4427 6 of 12
Int. J. Mol. Sci. 2019, 20, x 6 of 11 
 
 
Figure 4. µCT-derived measurement of the fifth lumbar vertebral body cancellous bone from Cre-
negative (white bars) and 10kbDmp1-Cre-positive (grey bars) Twist1f/f mice at 16 wk of age, treated 
with or without sclerostin antibody (Scl-Ab) for 6 wk prior to sacrifice. (A) Representative 3D cutaway 
reconstructions of the fifth lumbar vertebra in A-P view (top row) and S-I view (bottom row). Female 
mice are in the top of the panel, males in the bottom. Quantitative differences in lumbar vertebra 5 
(LV5) (B) trabecular bone volume fraction (BV/TV), (C) trabecular thickness (Tb.Th), (D) trabecular 
bone mineral content (Tb.BMC), (E) and trabecular separation (Tb.Sp) are shown for female (left side 
of each panel) and male (right side of each panel) mice. Data were tested for significance using two-
way ANOVA within sex, with Twist1 status and antibody as the main effects (plus interaction), which 
are reported in the corner or base of each sex grouping; n = 8–11/group. 
 
Figure 5. (A) Representative force-displacement curves from monotonic three-point bending tests to 
failure conducted on whole femora from female Cre-negative and 10kbDmp1-Cre-positive Twist1f/f 
mice at 16 wk of age, treated with or without sclerostin antibody (Scl-Ab) for 6 wk prior to sacrifice. 
Quantification of (B) ultimate force, (C) stiffness, and (D) energy to ultimate force revealed strong 
antibody effects in both Twist-replete and -deficient mice, but no effect of the Twist mutation alone 
was detected. Data were tested for significance using two-way ANOVA within sex, with Twist1 status 
and antibody as the main effects (plus interaction), which are reported in the corner or base of each 
sex grouping; n = 8–11/group. 
Figure 4. µCT-derived measurement of the fifth lumbar vertebral body cancellous bone from
Cre-negative (white bars) and 10kbDmp1-Cre-positive (grey bars) Twist1f/f mice at 16 wk of age,
treated with or without sclerostin antibody (Scl-Ab) for 6 wk prior to sacrifice. (A) Representative 3D
cutaway reconstructions of the fifth lumbar vertebra in A-P view (top row) and S-I view (bottom row).
Female mice are in the top of the panel, males in the bottom. Quantitative differences in lumbar vertebra
5 (LV5) (B) trabecular bone volume fraction (BV/TV), (C) trabecular thickness (Tb.Th), (D) trabecular
bone mineral content (Tb.BMC), (E) and trabecular separation (Tb.Sp) are shown for female (left side of
each panel) and male (right side of each panel) mice. Data were tested for significance using two-way
ANOVA within sex, with Twist1 status and antibody as the main effects (plus interaction), which are
reported in the corner or base of each sex grouping; n = 8–11/group.
I t.      x  f 1 
 
 
Figure 4. µCT-derived measurement of the fifth lumbar vertebral body cancellous bone from Cre-
negative (white bars) and 10kbDmp1-Cre-positive (grey bars) Twist1f/f mice at 16 wk of age, treated 
with or without sclerostin antibody (Scl-Ab) for 6 wk prior to sacrifice. (A) Representative 3D cutaway 
reconstructions of the fifth lumbar vertebra in A-P view (top row) and S-I view (bottom row). Female 
mice are in the top of the panel, males in the bottom. Quantitative differences in lumbar vertebra 5 
(LV5) (B) trabecular bone volume fraction (BV/TV), (C) trabecular thickness (Tb.Th), (D) trabecular 
bone mineral content (Tb.BMC), (E) and trabecular separation (Tb.Sp) are shown for female (left side 
of each panel) and male (right side of each panel) mice. Data were tested for significance using two-
way ANOVA within sex, with Twist1 status and antibody as the main effects (plus interaction), which 
are reported in the corner or base of each sex grouping; n = 8–11/group. 
 
Figure 5. (A) Representative force-displacement curves from monotonic three-point bending tests to 
failure conducted on whole femora from female Cre-negative and 10kbDmp1-Cre-positive Twist1f/f 
mice at 16 wk of age, treated with or without sclerostin antibody (Scl-Ab) for 6 wk prior to sacrifice. 
Quantification of (B) ultimate force, (C) stiffness, and (D) energy to ultimate force revealed strong 
antibody effects in both Twist-replete and -deficient mice, but no effect of the Twist mutation alone 
was detected. Data were tested for significance using two-way ANOVA within sex, with Twist1 status 
and antibody as the main effects (plus interaction), which are reported in the corner or base of each 
sex grouping; n = 8–11/group. 
i . t ti i l t t i t i t i t t t
f il r c t on whole femora from female Cre-negative and 10kbD p1- re- ositi Twist1f/f
ice t f e, tre te it r it t scler sti ti ( cl- ) f r ri r t s crifice.
a tificati f ( ) lti ate f rce, ( ) stiff ess, a ( ) e er t lti ate f rce re eale str
antibody effects in both Twist-replete and -deficient mice, but no effect of the Twist mutation alone was
detected. Data were tested for significance using two- ay ANOVA within sex, with Twist1 status and
antibody as the main effects (plus interaction), which are reported in the corner or base of each sex
grouping; n = 8–11/group.
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Similar to the results reported for DXA measurements, the µCT measurements and mechanical
testing revealed a strong effect of Scl-Ab treatment for every endpoint analyzed, but no significant
interaction terms were found for genotype by treatment, suggesting that the Twist1 bone deletion did
not significantly change the influence of Scl-Ab on cancellous or cortical properties.
3. Discussion
Our goal in this study was to determine whether preventing Twist1 upregulation during sclerostin
inhibition could improve the efficacy of sclerostin antibody therapy. That goal was prompted in
part by our previously published RNAseq-derived data showing a 2.6-fold upregulation in Twist1
expression in osteocyte-enriched lysates from Scl-Ab-treated mice as compared with saline-treated
mice [11]. Similarly, the Amgen group reported that Twist1 was among the most highly upregulated
genes in osteocyte-enriched lysates from rats exposed to Scl-Ab, reaching a three-fold increase by
7 days post Scl-Ab injection [20]. Scl-Ab is known to induce self-regulating mechanisms on Wnt
signaling, including Sost and Dkk1 expression [9], which might serve to limit excessive bone formation.
We surmised that Twist1 might be a component of the self-regulating mechanism of Scl-Ab, given
that Twist1 suppresses osteogenesis and mineralization in culture [21]. Treatment with Scl-Ab was
equally efficacious in the skeletons of Twist1 mutants and controls, suggesting that upregulation of
Twist1 is not a functional compensatory mechanism that restrains the bone-building effects of sclerostin
neutralization. It is possible that deletion of Twist1 earlier in the MSC/osteoblast lineage would have
more profound effects on Scl-Ab efficacy. It is noteworthy that we observed an increase in Twist1
expression with Scl-Ab but not Dkk1-Ab injection; we have previously reported that longer-term
Scl-Ab (but not Dkk1-Ab) treatment is anabolic in bone.9 Nevertheless, Twist1 inhibition is unlikely to
improve Scl-Ab efficacy in patients, despite its baseline effect on bone homeostasis.
A second goal of this study was to learn whether late-stage deletion of Twist1 induces skeletal
effects that enhance bone mass, while avoiding development and patterning defects normally associated
with Twist1 mutations. We found that Twist1 deletion from Dmp1-expressing cells resulted in a mild
but significant increase in bone mass, particularly in older (beyond 6 wk) mice and preferentially in
the cortical bone compartment; increased cancellous bone properties were observed only in female
mutants. The significant increase in midshaft femur size (Tt.Ar) and estimated torsional rigidity (pMOI)
observed among Cre-positive mice did not translate into improved mechanical competence of the
bones, though there was a trend of increased strength among Cre-positive mice.
In contrast to our finding that Twist1 expression increases in mice where Wnt signaling is elevated
by sclerostin neutralization, tonic activation of the same pathway in osteoblasts from Lrp5-HBM
patients appears to reduce Twist1 expression compared to controls [22]. The difference in Twist1
dynamics might be related to species differences, or to a chronic versus acute stimulation of Wnt
signaling in bone. It is also possible that since recombination in the osteocyte population was incomplete
(Figure 1C), perhaps antibody treatment was able to upregulate Twist expression among osteocytes
with unrecombined alleles. In addition, we have previously reported that sclerostin expression is
downregulated by mechanical loading of osteocytes [23]. In the same cell population, loading induces
a significant increase in Twist1 expression that is temporally preceded by Sost downregulation [24].
Whether Twist1 plays a role in mechanical signaling remains to be determined.
The role of Twist1 in postnatal bone has not been widely studied, and where it has, its role in
mineralized tissue homeostasis is equivocal. For example, PTH has been reported to both increase [25]
and decrease [26] Twist1 expression. Twist1 haploinsufficiency in mice is reported to improve skeletal
healing and osteogenesis around defects [27], but other reports indicate it reduces bone formation [28].
Moreover, Twist1 overexpression promotes odontoblast differentiation [29] but impairs cementoblast
differentiation [30]. As a widely expressed transcription factor, the role of Twist1 in regulating postnatal
skeletal cell fate and activity is likely to be highly context-dependent. Twist1 is a candidate target for
non-small cell lung cancer therapy [31], and development of small molecule inhibitors of Twist1 is an
area of great interest [32]. If a Twist1 inhibitor becomes clinically available, our data indicate that it is
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unlikely to have negative effects on bone tissue. Moreover, Twist1 inhibition is unlikely to interfere
with the anabolic effects of Romosozumab therapy.
One potential limitation of our experiments is that they were conducted entirely in in vivo models.
There is a paucity of information regarding the general function of Twist1 in osteocytes, which could be
addressed using cell culture approaches involving Twist1 knockdown or overexpression in osteocytes.
However, it is difficult to study sclerostin-mediated osteocyte biology in culture. Many of the common
osteocyte cell lines express sclerostin at very low levels and thus antibody-based inhibition of such
a scarce target is challenging. For this reason, we pursued the experiments using an in vivo model
where osteocyte-selective Twist1 regulation of skeletal physiology, particularly in response to sclerostin
antibody, could be studied.
In summary, deletion of Twist1 from the osteocyte/late-stage osteoblast population resulted in
increased bone mass and density, which was more robustly manifested in young adult and adult mice.
Treatment with sclerostin antibody was equally efficacious in enhancing bone mass, size, and strength
in Twist1 mutants and WT mice. While elucidation of the self-regulation phenomenon associated with
sclerostin inhibition is an area of great interest, Twist1 transcriptional activity does not appear to be
among those factors that induce restraint on the effects of sclerostin neutralization in bone.
4. Materials and Methods
4.1. Mice
Development of the conditional Twist1-flox mouse model has been reported elsewhere [33]. Briefly,
the Twist1-flox allele harbors head-to-toe loxP sequences flanking exons 1 and 2 of the endogenous Twist1
gene. Recombination of the loxP sites results in complete deletion of the entire open reading frame,
which is contained in exon 1. The Rosa26-LacZ Cre-reporter line (B6.129S4-Gt(ROSA)26Sortm1Sor/J)
has been described elsewhere [34]. Briefly, these mice harbor a loxP-flanked DNA STOP sequence
preventing expression of the downstream lacZ cassette. When crossed with a Cre transgenic strain, the
stop sequence is removed and lacZ is expressed in cells/tissues where Cre is expressed. Development
of the 10kbDmp1-Cre transgenic mouse model has been reported elsewhere [35]. Briefly, these mice
harbor a transgene expressing Cre recombinase driven by a 9.6kb fragment of the mouse Dentin
Matrix Protein-1 promoter. All mouse colonies were maintained on a C57BL/6 background. For all
experiments, Cre-negative Twist1f/f littermates were used as controls. All mouse procedures were
performed in accordance with the IACUC guidelines and approvals (approval date: 11/17/2017).
4.2. Antibodies
Details of the development of sclerostin- and Dkk1-neutralizing antibodies has been reported
elsewhere [36,37]. Briefly, the sclerostin antibody (Scl-Ab) is a ratized version of a mouse monoclonal
antibody that neutralizes mouse sclerostin. The Dkk1 antibody is a neutralizing rat monoclonal raised
against mouse Dkk1. For the functional study, Scl-Ab was injected into mice subcutaneously (subQ) at
25 mg/kg, 200 µL per injection, twice per week for 5 wk, beginning at 10 wk of age. Vehicle treatment
was the saline buffer in which the antibodies were made, and was injected with identical frequency,
volume, and duration as described for antibody injections. For short-term gene expression studies,
either Scl-Ab or Dkk1-Ab were injected once at 25 mg/kg each into 10-wk-old mice, and the mice were
sacrificed 2 days later.
4.3. Dual-Energy X-Ray Absorptiometry (DXA)
Collection of serial DXA measurements on live mice are described and validated elsewhere [11].
Briefly, mice were anesthetized via inhalation of 2.5% isoflurane (IsoFlo; Abbott Laboratories,
North Chicago, IL) mixed with O2 (1.5 liter/min) for a total ~8 min, including both induction and
scanning. The mice were placed in prone position on a specimen tray within the scanner. Whole-body
scans were analyzed regionally using the Lunar region of interest (ROI) tools. The ROI for the spine
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included the third (LV3) through fifth (LV5) lumbar vertebrae. The ROI for the hindlimb included all
skeletal tissue distal the acetabulum. The ROI for the whole body included all skeletal tissues caudal
to the CV1/skull boundary. Serial scans were performed at 4, 6, 9, 12, and 16 wk of age. Bone mineral
density (BMD) was measured for each ROI scan.
4.4. Micro-Computed Tomography (µCT)
Formalin-fixed femora and fifth lumbar vertebrae were scanned, reconstructed, and analyzed as
previously described [11]. Briefly, 10-µm resolution, 50-kV peak tube potential and 151-ms integration
time were used to collect scans on a Scanco uCT-35 tomographer. The distal 60% of each femur and the
entire body of each vertebra were scanned. Standard parameters related to cancellous and cortical
bone architecture were measured [38].
4.5. β-Galactosidase Staining, Twist1 Expression, and Twist1 Genomic Recombination
Whole femora were removed from 8-wk-old 10kbDmp1-Cre-positive and -negative mice that
also carried the LacZ reporter. Femora were fixed overnight in 0.5% glutaraldehyde, then reacted
for 1 h in β-gal staining solution (1 mg/mL X-gal, 5 mM potassium ferricyanide, 5 mM potassium
ferrocyanide) at 37 ◦C. Samples were rinsed in tap water and photographed. Twist1 RNA expression
was measured in pulverized femur and tibia cortices from 8-wk-old C57BL/6J mice that had been
treated with antibody. Total RNA was isolated using the Trizol method and reverse transcribed into
cDNA using random hexamers. Twist1 and Rplp2 (housekeeping transcript) were measured using the
SYBR green technique on an ABI QuantStudio 7 Flex thermocycler. The ∆∆CT method was used to
calculate relative expression, which was normalized to Rplp2 for each sample. Recombination of the
floxed allele was assessed by real-time PCR of purified genomic DNA (gDNA) extracted from cortical
bone tissue from the distal tibia. Both primers were located within the floxed region (Figure 1C).
Recombination of Twist 1 gDNA was standardized to Apolipoprotein B gDNA.
4.6. Mechanical Properties
Parameters related to whole-bone strength were measured using three-point bending tests
on isolated femora, as previously described [39]. Briefly, each femur was loaded to failure in
monotonic compression, during which force and displacement were collected every 0.01 s. From the
force/displacement curves, ultimate force, stiffness, and energy to failure were calculated using standard
equations [40].
4.7. Statistics
Statistical analyses were computed with JMP (version 12.0, SAS Institute Inc., Cary, North Carolina,
USA). The tomography and biomechanical endpoints were analyzed with two-way ANOVA within
sex, using Cre status and injection treatment as the main effects. When at least one main effect
was significant, interaction terms were calculated and tested for significance. Time-series data were
analyzed with repeated-measures ANOVA. Statistical significance was taken at p < 0.05. Two-tailed
distributions were used for all analyses. Data are presented as mean ± SEM. A minimum of eight
animals were included in each group (n = 8–11/group).
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